Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.33 |
| ▸ | ACP3 | P15309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8634074 | 0.85 | AOC3 (0.44) | AOC3HTR6SLC6A4GAAIDO1 | |
| SCHEMBL5009193 | 0.85 | AOC3 (0.48) | AOC3HTR6SLC6A4GAAIDO1 | |
| SCHEMBL8986918 | 0.85 | AOC3 (0.44) | AOC3HTR6SLC6A4GAAIDO1 | |
| SCHEMBL4864455 | 0.80 | CNR1 (0.42) | AOC3HTR6GAA | |
| SCHEMBL9063602 | 0.72 | AOC3 (0.43) | AOC3SLC6A4IDO1TDO2SLC6A2 | |
| SCHEMBL8986774 | 0.71 | AOC3 (0.39) | AOC3SLC6A4SLC6A2SLC6A3PDE1B | |
| SCHEMBL24615882 | 0.70 | AOC3 (0.64) | AOC3SLC6A4IDO1TDO2SLC6A2 | |
| SCHEMBL14587100 | 0.70 | AOC3 (0.64) | AOC3HTR6SLC6A4IDO1TDO2 | |
| SCHEMBL7153432 | 0.69 | AOC3 (0.50) | AOC3HTR6SLC6A4IDO1TDO2 | |
| SCHEMBL7003007 | 0.69 | AOC3 (0.43) | AOC3HTR6SLC6A4GAAIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470713-B2 | Imidazole based kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-20050187218-A1 | Imidazole based kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187218-A1 | Imidazole based kinase inhibitors | MAP3K19, MAP3K1, ABL1 | AOC3 3915/4885HTR6 3210/4885SLC6A4 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.